Case Study: BioCryst Pharmaceuticals accelerates BCX4161 development with Quotient Sciences Translational Pharmaceutics

BioCryst Pharmaceuticals accelerates BCX4161 development with Quotient Sciences

BioCryst Pharmaceuticals, a small biotech company, was developing BCX4161 for hereditary angioedema and required a partner to ensure their delivery timelines could be met. They approached Quotient Sciences for its expertise and experience to help accelerate the program.

Quotient Sciences applied its Translational Pharmaceutics platform and First-in-Human program to the development of BCX4161. This solution accelerated BioCryst's development timelines, allowing them to successfully hit their key deadlines.

BioCryst Pharmaceuticals